WP_Query Object
(
[query] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
)
[query_vars] => Array
(
[post_type] => post
[posts_per_page] => 3
[post_status] => publish
[orderby] => rand
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] =>
[comments_per_page] => 50
[no_found_rows] =>
[order] =>
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wp_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID
FROM wp_posts
WHERE 1=1 AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
ORDER BY RAND()
LIMIT 0, 3
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:50:15
[post_modified_gmt] => 2024-11-19 15:50:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 3469
[post_author] => 3
[post_date] => 2020-05-05 08:25:54
[post_date_gmt] => 2020-05-05 08:25:54
[post_content] => *This list will be updated as opportunities arise. (Updated 7.21.20)
The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”. Rolling deadline - details here: https://grants.nih.gov/grants/guide/pa-files/PAR-20-256.html#_Section_I._Funding
Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American. The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Learn more: https://www.poctrn.org/radx
Pfizer has released a Request for Proposals (RFP) to provide financial support for organizations producing independent educational programs and quality improvement initiatives designed to combat this evolving crisis. This competitive grant program from Pfizer Global Medical Grants (GMG) involves a publicly posted RFP that provides details regarding a specific area of interest, sets timelines for review and approval, and uses an internal review process to make final grant decisions. For this RFP, organizations are invited to submit an application addressing the gaps in knowledge and practice of COVID-19 management as outlined here.
Mozilla has created a COVID-19 Solutions Fund as part of the Mozilla Open Source Support Program (MOSS). Through this fund, awards of up to $50,000 each will be provided to open source technology projects which are responding to the COVID-19 pandemic in some way.
As part of the COVID-19 Solutions Fund, applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related misinformation)will be accepted. More details here. Application here.
The COVID-19 Manufacturing Grants, part of the Jeff Lawrence Innovation Fund, are designed to aid existing New York State small to medium-sized manufacturing companies that can meet prevailing FDA requirements and can quickly accelerate production of personal protective equipment and respiratory care equipment that has been depleted due to the COVID-19 outbreak. Full details here. (Deadline April 17, 2020)
Multiple Notices of Special Interest include administrative supplements and emergency competitive revisions funding for current grantees; SBIR/STTR opportunities; and investigator-initiated research opportunities. Current grantees and new applicants are encouraged to apply immediately. More here.
Fast Funding for COVID-19 Science. Scientist at academic institutions currently working on a COVID-19 related project and in need of funding are invited to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made in under 48 hours. More: fastgrants.org
Multiple Agency NOSI listed here.
National Institute of Allergy and Infectious Diseases: Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed) RFA-AI-20-028
Administrative Supplements to Existing NIH Grants and Cooperative Agreements: Funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award. More.
Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements: Funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner. More.
Phase I proposals should focus on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis. Areas of research include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations. To apply, you must first develop and submit a Project Pitch at https://seedfund.nsf.gov/apply/. Assuming your pitch is approved, you will be invited by NSF to submit a grant application. More information here.
This award will be presented to a single investigator or team of up to two investigators that develops a “transformative idea” to resolve challenges, advance frontiers, and set new paradigms in areas of immense potential benefit to DoD and the nation at large. BRO-20-NEWTON (5/5/20 deadline)
Established by The Gates Foundation and Wellcome, this initiative aims to accelerate and evaluate new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. The COVID-19 Therapeutics Accelerator will not be conducting a traditional funding call. To learn more about the funding process, or how to invest in the accelerator, contact epidemics@wellcome.ac.uk
Stony Brook University Small Business Development Center is available to assist business owners trough the abundance of resources available for your particular business/industry and to avoid the most common mistake of incomplete or inaccurate Economic Injury Disaster Assistance Loan applications. Visit their website for more information.
Stony Brook University's College of Engineering and Applied Sciences' Vertically Integrated Project Program is focusing special attention on the urgent needs of the COVID-19 pandemic. Learn more.
The CoVent-19 Challenge invites engineers, innovators, designers, and makers to produce rapidly deployable designs for mechanical ventilators. Launching on April 1, 2020, the deadline for the open-entry round of competition is May 1, 2020. Round 2 of the challenge is an invitation-only competition with a deadline of June 1, 2020. More: coventchallenge.com
The funding opportunities listed here are posted on the Pivot database, grants.gov, NIH Guide for Grants and Contracts, and nsf.gov. Detailed information on NIH funding opportunities and other guidance related to COVID-19 can be found here. Investigators should check eligibility and obtain any necessary approvals before applying.
Stony Brook University Office of the Vice President for Research, together with the Institute for Engineering-Driven Medicine, announce this special initiative COVID-19 seed funding opportunity.
The purpose of this program is to seed research that has a direct connection to the current COVID-19 pandemic.Applications are due April 10. Details about eligibility, award amounts and application process can be found here.
Businesses with capabilities relevant to needed medical equipment and supplies email to COVID19supplies@esd.ny.gov.
Businesses interested in selling products to the state should contact Simonida Subotic at 646-522-8477 or covid19supplies@exec.ny.gov.
Businesses interested in receiving state funding to manufacture PPE products should contact Eric Gertler at 212-803-3100 or COVID19supplies@esd.ny.gov.
Indie Bio is seeking up to 8 startups to receive a minimum of $250,000 each to pursue the development of diagnostics, therapeutics, vaccines, disinfection, and other solutions addressing the worldwide problem of emerging infectious diseases. More.
BARDA BAA (no funding limit)
Novel Coronavirus EZ-BAA (solicitations for funding up to $750K)
**NEW** SUNY Research Seed Grant Program RFP #20-03-COVID & Submission form.
Aggregate list of opportunities: https://www.rfsuny.org/about-us/covid-19/covid-19-funding/
Resource page includes Business Resource Center, Service Provider Directory and Coronoavirus Hub where companies can share what they need and how they can help.
the Challenge is lead by Code Life.ca and the Montreal General Hospital foundations. The designs are due end of March 2020. The details and rules are posted there, and participants can sign up to begin: https://www.agorize.com/en/challenges/code-life-challenge/
OTHER CHALLENGES
Business Incubator Association of New York State - Innovate to Ventilate
Hauppauge Industrial Association of Long Island (HIA-LI) Pivot to PPE
RESOURCES
COVID-19 Open Research Dataset (CORD-19)
Ginkgo commits $25M of free access to platform for partner COVID-19 projects
[post_title] => COVID-19 Funding and Resource Opportunities
[post_excerpt] => An aggregate list of COVID-19 related funding opportunities and technology and business related resources. This list will be updated as opportunities arise.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => covid-19-resources
[to_ping] =>
[pinged] =>
https://indiebio.co/indiebio-covid-response/
[post_modified] => 2020-07-21 13:20:53
[post_modified_gmt] => 2020-07-21 13:20:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=3469
[menu_order] => 71
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 1001
[post_author] => 1
[post_date] => 2014-06-04 05:56:55
[post_date_gmt] => 2014-06-04 05:56:55
[post_content] => CFB Client Company, Intensity Therapeutics, Inc. established a cooperative research and development agreement (CRADA), with the National Institute of Health?s National Cancer Institute (NCI) Vaccine Branch. Intensity Therapeutics was awarded the CRADA by the NCI to study the efficacy and mechanism of action of Intensity?s in situ chemovaccination products using in vivo models of cancer. Read the full press release here.
[post_title] => Intensity Therapeutics Awarded CRADA from National Cancer Institute
[post_excerpt] => A CFB Client Company established a cooperative research and development agreement (CRADA), with the National Institute of Health?s National Cancer Institute (NCI) Vaccine Branch.
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => intensity-therapeutics-awarded-crada-from-national-cancer-institute
[to_ping] =>
[pinged] =>
[post_modified] => 2015-01-28 17:06:52
[post_modified_gmt] => 2015-01-28 17:06:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/new/?p=1001
[menu_order] => 229
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2899
[post_author] => 1
[post_date] => 2017-12-15 20:24:05
[post_date_gmt] => 2017-12-15 20:24:05
[post_content] => Clinton Rubin, PhD, Director of the Center for Biotechnology and Distinguished Professor of Biomedical Engineering at Stony Brook University has been elected as a Fellow of the National Academy of Inventors (NAI). According to the NAI, election as an NAI Fellow is a high honor bestowed upon academic innovators and inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions and innovations that have made a tangible impact on quality of life, economic development, and the welfare of society. Dr. Rubin and fellow SBU Distinguished Professor Dr. Arie Kaufman will be inducted as NAI Fellows during its 2018 national meeting in Washington, DC, on April 5.
With the election of the 2017 class there are now 912 NAI Fellows, representing over 250 research universities and governmental and non-profit research institutes. The 2017 Fellows are named inventors on nearly 6,000 issued U.S. patents, bringing the collective patents held by all NAI Fellows to more than 32,000 issued U.S. patents.
Professor Rubin, founding chair of Stony Brook’s Department of Biomedical Engineering, pioneered research in understanding the role of mechanical signals in the musculoskeletal system and has patented technology that includes use of low frequency mechanical signals (vibrations) to combat disease like osteoporosis and obesity.
More on Dr. Rubin’s election as an NAI Fellow can be access here and here.
[post_title] => CFB Director Elected Fellow, National Academy of Inventors (NAI)
[post_excerpt] => Clinton Rubin, PhD, Director of the Center for Biotechnology has been elected a Fellow of the National Academy of Inventors (NAI).
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => cfb-director-elected-fellow-national-academy-of-inventors-nai
[to_ping] =>
[pinged] =>
[post_modified] => 2018-01-23 14:38:34
[post_modified_gmt] => 2018-01-23 14:38:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => http://centerforbiotechnology.org/?p=2899
[menu_order] => 131
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 4
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4439
[post_author] => 3
[post_date] => 2024-07-30 15:29:07
[post_date_gmt] => 2024-07-30 19:29:07
[post_content] =>
CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.
The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.
Read more about IAMBIC and their recent funding here.
[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
[post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations.
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-19 10:50:15
[post_modified_gmt] => 2024-11-19 15:50:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4439
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 261
[max_num_pages] => 87
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] =>
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] => 1
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] =>
[query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
